title: How cost-effective is hepatitis C virus treatment for people who inject drugs?
authors.forename: Natasha K
authors.initials: NK
authors.lastname: Martin
authors.forename: Peter
authors.initials: P
authors.lastname: Vickerman
authors.forename: Alec
authors.initials: A
authors.lastname: Miners
authors.forename: Matthew
authors.initials: M
authors.lastname: Hickman
mesh_terms: D000998:Antiviral Agents / Q000191:economics*; D005260:Female; D019698:Hepatitis C, Chronic / Q000191:economics*; D006801:Humans; D016898:Interferon-alpha / Q000191:economics*; D008297:Male; D011092:Polyethylene Glycols / Q000191:economics*; D011994:Recombinant Proteins / Q000191:economics; D012254:Ribavirin / Q000191:economics*; D015819:Substance Abuse, Intravenous / Q000191:economics*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a